Access Financial Services Inc. Has $1.22 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Access Financial Services Inc. trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 15.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,246 shares of the medical research company’s stock after selling 790 shares during the quarter. Access Financial Services Inc.’s holdings in Amgen were worth $1,223,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Roundview Capital LLC boosted its holdings in shares of Amgen by 1.3% during the first quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock worth $2,027,000 after purchasing an additional 107 shares during the period. Merit Financial Group LLC boosted its holdings in shares of Amgen by 39.2% during the first quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock worth $555,000 after purchasing an additional 647 shares during the period. Ergoteles LLC acquired a new stake in shares of Amgen during the first quarter worth approximately $219,000. First Western Trust Bank acquired a new stake in shares of Amgen during the first quarter worth approximately $334,000. Finally, Fuller & Thaler Asset Management Inc. raised its position in Amgen by 2.1% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after acquiring an additional 513 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 0.7 %

Shares of AMGN stock opened at $284.32 on Friday. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm’s fifty day simple moving average is $290.09 and its 200 day simple moving average is $280.70. The firm has a market capitalization of $152.37 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 2.70 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the company earned $4.09 earnings per share. The business’s revenue was up 19.8% compared to the same quarter last year. As a group, sell-side analysts predict that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. Amgen’s dividend payout ratio is currently 72.06%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on AMGN shares. Royal Bank of Canada raised their price objective on shares of Amgen from $303.00 to $329.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Raymond James started coverage on shares of Amgen in a research report on Thursday. They set a “market perform” rating on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Finally, SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.